Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The resveratrol-induced cardiac protection was studied in Zucker obese rats. Rats were divided into five groups: group 1, lean control; group 2, obese control (OC); group 3, obese rats treated orally with 5 mg·kg−1·day−1 of resveratrol (OR) for 2 wk; group 4, obese rats received 10% glucose solution ad libitum for 3 wk (OG); and group 5, obese rats received 10% glucose for 3 wk and resveratrol (OGR) during the 2nd and 3rd wk. Body weight, serum glucose, and insulin were measured, and then hearts were isolated and subjected to 30 min of ischemia followed by 120 min of reperfusion. Heart rate, coronary flow, aortic flow, developed pressure, the incidence of reperfusion-induced ventricular fibrillation, and infarct size were measured. Resveratrol reduced body weight and serum glucose in the OR compared with the OC values (414 ± 10 g and 7.08 ± 0.41 mmol/l, respectively, to 378 ± 12 g and 6.11 ± 0.44 mmol/l), but insulin levels were unchanged. The same results were obtained for the OG vs. OGR group. Resveratrol improved postischemic cardiac function in the presence or absence of glucose intake compared with the resveratrol-free group. The incidence of ventricular fibrillation and infarct size was reduced by 83 and 20% in the OR group, and 67 and 16% in the OGR group, compared with the OC and OG groups, respectively. Resveratrol increased GLUT-4 expression and reduced endothelin expression and cardiac apoptosis in ischemic-reperfused hearts in the presence or absence of glucose intake. Thus the protective effect of resveratrol could be related to its direct effects on the heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“IN THE PAST THREE DECADES, an explosive increase in the number of people diagnosed with diabetes was seen worldwide (7, 48).”
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury
Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A. J., Murphy, M. P., & Sammut, I. A. (2005) · The FASEB Journal · doi:10.1096/fj.05-3718com · Cited by 618 · cited 1×
“The underlying mechanisms responsible for the development of diabetes are a complex interplay of various and potential factors, such as increased thrombotic potential (29), endothelial dysfunction (19), and increased oxidative stress (1).”
Diabetes in heart failure: prevalence and impact on outcome in the population
From, A. M., Leibson, C. L., Bursi, F., Redfield, M. M., Weston, S. A., Jacobsen, S. J., Rodeheffer, R. J., & Roger, V. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.024 · Cited by 295 · cited 1×
“Diabetes is a major risk factor for the development of cardiovascular diseases, which accounts largely for the high morbidity and mortality in diabetic populations (3, 17, 33).”
Yue, T.-L., Bao, W., Gu, J.-L., Cui, J., Tao, L., Ma, X.-L., Ohlstein, E. H., & Jucker, B. M. (2005) · Diabetes · doi:10.2337/diabetes.54.2.554 · Cited by 170 · cited 1×
“Glucose transport and glycolytic rates determine the extent of ischemia and the recovery of postischemic function in the myocardium (28, 39, 47).”
Sidell, R. J., Cole, M. A., Draper, N. J., Desrois, M., Buckingham, R. E., & Clarke, K. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1110 · Cited by 165 · cited 2×
“In obese and diabetic animal studies, increased ischemic damage has also been reported (20, 31), and normalization of cardiac metabolism in hearts from these animals has been shown to improve the recovery of cardiac function following an episode of ischemia-reperfusion (39).”
Atherton, H. J., Bailey, N. J., Zhang, W., Taylor, J., Major, H., Shockcor, J., Clarke, K., & Griffin, J. L. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00060.2006 · Cited by 159
Myocardial infarction and heart failure in the db/db diabetic mouse
Greer, J. J. M., Ware, D. P., & Lefer, D. J. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00583.2005 · Cited by 108 · cited 1×
“In obese and diabetic animal studies, increased ischemic damage has also been reported (20, 31), and normalization of cardiac metabolism in hearts from these animals has been shown to improve the recovery of cardiac function following an episode of ischemia-reperfusion (39).”
Cited by
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F., García-Conesa, M., & Espín, J. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 449
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H.-Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 437
Self-citationResveratrol: Its Biologic Targets and Functional Activity
Pervaiz, S., & Holme, A. L. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2412 · Cited by 405
Resveratrol addiction: To die or not to die
Shakibaei, M., Harikumar, K. B., & Aggarwal, B. B. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800148 · Cited by 316
Wong, R. H. X., Howe, P. R. C., Buckley, J. D., Coates, A. M., Kunz, I., & Berry, N. M. (2011) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.03.003 · Cited by 277
“The purported cardiovascular benefits of resveratrol from experimental evidence include defence against ischaemic-reperfusion injury (21-23), suppression of platelet aggregation (16, 24), enhanced antioxidant status (16, 25) and increased NO bioavailability through enhanced endothelial NO synthase expression in cultur…”
Background
Metadata
- Authors
- Lekli, I., Szabo, G., Juhasz, B., Das, S., Das, M., Varga, E., Szendrei, L., Gesztelyi, R., Varadi, J., Bak, I., Das, D. K., & Tosaki, A.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2008-02
- Volume
- 294
- Issue
- 2
- Pages
- H859-H866
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2102946509
- Cited by
- 113
- References
- 8
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.